DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine

StatusNot Yet Recruiting
PhasePhase 1
SponsorEccogene
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Eccogene
5 trials monitored
See 2 trials at risk
NASH / MASH
690 trials monitored
See 23 trials at risk
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK) of metformin (a MATE1/2-K probe substrate), midazolam (a CYP3A4 probe substrate), and caffeine (a CYP1A2 probe substrate).
Trial Details
NCT Number NCT07873229
Lead Sponsor Eccogene
Conditions
(from sponsor)		 Steatohepatitis, Nonalcoholic, Osteo Arthritis
Related terms Non-alcoholic Fatty Liver Disease
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov